Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > BUSINESS
BUSINESS
- Pfizer’s FY2016 Japan Sales Slide 7.4% on Price Cuts, Generic Erosions
March 9, 2017
- Fujifilm Succeeds at Increasing Anti-Inflammatory Action of Mesenchymal Stem Cells, Expects Uses in Regenerative Medicine
March 9, 2017
- Average Drug R&D Spending in Japan Up 1.46 Billion Yen in FY2015
March 8, 2017
- Ethical Drug Sales Down 6.8% in January: Crecon
March 8, 2017
- Avelumab Filed in Japan for Merkel Cell Carcinoma: Merck Serono/Pfizer
March 8, 2017
- Taiho Forms Canadian Unit for Lonsurf Rollout
March 8, 2017
- Edoxaban Study in Post-PCI AF Patients Underway: Daiichi Sankyo
March 8, 2017
- Fujifilm, Kyowa Kirin JV Wins Humira Patent Litigation in UK
March 7, 2017
- Mochida, Fuji Yakuhin Link Arms on Hyperuricemia Candidate
March 7, 2017
- Maruho Group to See 1st Overseas Launch Next Month with Acne Med
March 7, 2017
- Kanako Kikuchi to Become Japan Chief of GSK
March 7, 2017
- Otsuka to Buy Neurovance, Gets Its Hands on Non-Stimulant ADHD Med
March 6, 2017
- Bioverativ Japan Now Up and Running, Set to Keep Double-Digit Growth: President
March 3, 2017
- NCC, Daiichi Sankyo Begin PI on Mutant IDH1 Inhibitor for Glioma
March 2, 2017
- Fujifilm Creates Bio CDMO Division, Aims for 100 Billion Yen Sales in FY2023
March 2, 2017
- GSK Remains Strong Player in Respiratory, Japan Sales Slip 1.7%: Fauchet
March 1, 2017
- Nobelpharma Forms Preparatory Office for Overseas Biz
March 1, 2017
- ASKA Gets Asian Rights to Pieris’ Anemia Med
March 1, 2017
- Astellas, Affinivax Ink Global Partnership on Pneumococcal Vaccine
March 1, 2017
- Novo Files Once-Weekly GLP-1 in Japan
March 1, 2017
ページ
Let’s face it: in today’s world, changing jobs is a normal part of a successful career. But if it’s so normal, why does it feel so hard? For many people, the idea of leaving their current role brings a heavy…
Japan’s leading pharmaceutical wholesalers are bracing for a second consecutive year of profit declines, underscoring the growing challenge of generating…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…